Professor Sun Myint
Clatterbridge Cancer Centre (Private Clinic)
Professor Sun Myint introduced Papillon in 1993 and established the first facility in the UK at Clatterbridge Cancer Centre. He has now treated over 1600 patients with Papillon which is the world largest cohort treated by non-surgical method. He collaborated with his mentor Prof Jean Pierre Gerard (Nice) and Ariane a British company to produce a new contact X-ray machine. Since 2009 he used the first prototype Papillon 50. He is now working closely with Ariane to produce a second generation Papillon Plus machine which can treat other tumour sites such as breast, skin, eye, intra oral, intra vagina and intra operative radiation therapy.
NICE has now approved the Papillon treatment for rectal cancer in patients not suitable for surgery (IPG 532). For his contributions to oncology, he was awarded Honorary Professor by University of Liverpool in 2012. He led the UK Papillon team which won the prestigious BMJ award for ‘Cancer team of the year’ in May 2018.
Rectal cancer- Do patients have a choice?
Each year 12,000 patients are diagnosed with rectal cancer in the UK. The standard of care is radical surgery. Not all patients are suitable for surgery due to advancing age and their comorbidities. The mortality and morbidity is high following surgery in elderly patients. There is increase in ageing population in the UK. Contact X-ray brachytherapy[CXB] (Papillon) will be discuss as an alternative non-surgical treatment option for patients not suitable for surgery.
EVEN MORE SEMINARS
Dr Natalie Cook University of Manchester/Christie NHS Foundation Trust
Early phase trial options in prostate cancer
Prof Ingunn Holen Department of Oncology and Metabolism, University of Sheffield, UK
Tumour cell dormancy and breast cancer relapse
Dr Abeer Shabaan Queen Elizabeth Hospital Birmingham & University of Birmingham
Breast Pathology: Assessing tumour response to neoadjuvant chemotherapy and endocrine therapy– Pathological considerations
Dr Qamar Ghafoor University Hospital Birmingham
Stereotactive Radiotherapy Treatment for Primary Lung Cancers, and Oligometastasis to the Lungs.
Lucinda Billingham University of Birmingham - Cancer Research Clinical Trials Unit
National Lung Matrix Trial: testing multiple novel targeted treatments